Qiagen (NYSE:QGEN) Receives Average Recommendation of “Moderate Buy” from Analysts

Qiagen (NYSE:QGEN) has been assigned an average recommendation of “Moderate Buy” from the ten brokerages that are covering the firm, Marketbeat reports. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $51.15.

Several research firms have weighed in on QGEN. Jefferies Financial Group reaffirmed a “buy” rating and issued a $54.00 target price (up from $42.00) on shares of Qiagen in a research report on Tuesday, December 10th. Hsbc Global Res upgraded shares of Qiagen to a “hold” rating in a report on Thursday, October 17th. Finally, HSBC lowered shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 target price on the stock. in a report on Thursday, October 17th.

Qiagen Trading Down 1.2 %

QGEN opened at $45.40 on Friday. The company has a quick ratio of 1.89, a current ratio of 2.17 and a debt-to-equity ratio of 0.39. The firm has a market cap of $10.36 billion, a P/E ratio of 116.41, a P/E/G ratio of 3.57 and a beta of 0.35. Qiagen has a 52 week low of $39.03 and a 52 week high of $47.44. The business has a fifty day simple moving average of $43.21 and a 200-day simple moving average of $43.71.

Institutional Investors Weigh In On Qiagen

A number of hedge funds and other institutional investors have recently modified their holdings of QGEN. Tidal Investments LLC purchased a new position in Qiagen in the third quarter valued at $490,000. Wilmington Savings Fund Society FSB acquired a new position in shares of Qiagen during the 3rd quarter worth about $53,000. Sanctuary Advisors LLC boosted its position in shares of Qiagen by 24.8% during the 3rd quarter. Sanctuary Advisors LLC now owns 19,506 shares of the company’s stock worth $834,000 after acquiring an additional 3,878 shares in the last quarter. M&T Bank Corp increased its holdings in shares of Qiagen by 1.1% in the 3rd quarter. M&T Bank Corp now owns 85,649 shares of the company’s stock valued at $3,876,000 after acquiring an additional 931 shares during the last quarter. Finally, Barclays PLC raised its position in shares of Qiagen by 170.6% during the 3rd quarter. Barclays PLC now owns 1,849,004 shares of the company’s stock worth $84,259,000 after acquiring an additional 1,165,594 shares in the last quarter. 70.00% of the stock is currently owned by institutional investors and hedge funds.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.